S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
7 Stocks That Will Drive the Weight Loss Drugs Market
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
7 Stocks That Will Drive the Weight Loss Drugs Market
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
7 Stocks That Will Drive the Weight Loss Drugs Market
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
7 Stocks That Will Drive the Weight Loss Drugs Market
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:KRTX

Karuna Therapeutics (KRTX) Stock Price, News & Analysis

$329.83
+0.09 (+0.03%)
(As of 03/18/2024)
Today's Range
$329.75
$329.99
50-Day Range
$313.42
$329.83
52-Week Range
$158.38
$329.99
Volume
1.87 million shs
Average Volume
832,048 shs
Market Capitalization
$12.60 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$293.92

Karuna Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
10.9% Downside
$293.92 Price Target
Short Interest
Healthy
5.16% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.30mentions of Karuna Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$7.92 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($11.96) to ($7.31) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.64 out of 5 stars

Medical Sector

877th out of 938 stocks

Pharmaceutical Preparations Industry

410th out of 441 stocks

KRTX stock logo

About Karuna Therapeutics Stock (NASDAQ:KRTX)

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

KRTX Stock Price History

KRTX Stock News Headlines

Karuna Therapeutics, Inc. (NASDAQ:KRTX) Short Interest Update
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
KRTX May 2024 210.000 call
A lot of people are making this costly mistake
You may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time.
1KRTX : Karuna Therapeutics: Q4 Earnings Insights
Karuna Therapeutics: Getting Sold Short
KRTX Mar 2024 320.000 call
KRTX Mar 2024 260.000 put
KRTX Mar 2024 330.000 call
KRTX Mar 2024 280.000 put
See More Headlines
Receive KRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Karuna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KRTX
Fax
N/A
Employees
339
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$293.92
High Stock Price Target
$330.00
Low Stock Price Target
$225.00
Potential Upside/Downside
-10.9%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
16 Analysts

Profitability

Net Income
$-433,680,000.00
Pretax Margin
-66,209.48%

Debt

Sales & Book Value

Annual Sales
$650,000.00
Price / Sales
19,383.86
Book Value
$33.24 per share

Miscellaneous

Free Float
33,157,000
Market Cap
$12.60 billion
Optionable
Optionable
Beta
1.18
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Andrew Craig Miller Ph.D. (Age 42)
    Founder and President of Research & Development
    Comp: $835.4k
  • Dr. Stephen K. BrannanDr. Stephen K. Brannan (Age 68)
    Chief Medical Officer
    Comp: $751.75k
  • Mr. William Meury (Age 56)
    President, CEO & Director
  • Mr. Jason Parker Brown
    Chief Financial Officer
  • Ms. Alexis Smith
    Vice President of Corporate Affairs & Investor Relations
  • Ms. Mia Kelley J.D.
    General Counsel
  • Mr. Frank Truslow
    Senior Vice President of Corporate Development
  • Mr. Jonathan Rosin
    Chief Human Resources Officer
  • Dr. Alan Breier
    Chair of Scientific Advisory Board & Chief Clinical Advisor
  • Dr. Ronald N. Marcus M.D. (Age 66)
    Senior Vice President of Medical

KRTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Karuna Therapeutics stock right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Karuna Therapeutics in the last twelve months. There are currently 10 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" KRTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KRTX, but not buy additional shares or sell existing shares.
View KRTX analyst ratings
or view top-rated stocks.

What is Karuna Therapeutics' stock price target for 2024?

16 analysts have issued twelve-month price objectives for Karuna Therapeutics' stock. Their KRTX share price targets range from $225.00 to $330.00. On average, they expect the company's stock price to reach $293.92 in the next year. This suggests that the stock has a possible downside of 10.9%.
View analysts price targets for KRTX
or view top-rated stocks among Wall Street analysts.

How have KRTX shares performed in 2024?

Karuna Therapeutics' stock was trading at $316.51 on January 1st, 2024. Since then, KRTX shares have increased by 4.2% and is now trading at $329.83.
View the best growth stocks for 2024 here
.

When is Karuna Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our KRTX earnings forecast
.

How were Karuna Therapeutics' earnings last quarter?

Karuna Therapeutics, Inc. (NASDAQ:KRTX) released its quarterly earnings results on Thursday, February, 22nd. The company reported ($3.01) EPS for the quarter, missing analysts' consensus estimates of ($2.65) by $0.36. The firm's revenue was down 100.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($2.22) earnings per share.

What other stocks do shareholders of Karuna Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karuna Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Pfizer (PFE), Alibaba Group (BABA), Johnson & Johnson (JNJ), AT&T (T), Target (TGT) and Walt Disney (DIS).

When did Karuna Therapeutics IPO?

Karuna Therapeutics (KRTX) raised $70 million in an initial public offering on Friday, June 28th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Karuna Therapeutics' major shareholders?

Karuna Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Capital International Investors (11.20%), Vanguard Group Inc. (8.55%), Vanguard Group Inc. (8.45%), Price T Rowe Associates Inc. MD (5.20%), Wellington Management Group LLP (2.97%) and Brown Advisory Inc. (0.88%). Insiders that own company stock include Andrew Craig Miller, Atul Pande, James Healy, Jeffrey M Jonas, Laurie J Olson, Laurie J Olson, Stephen K Brannan, Steven M Paul and Troy A Ignelzi.
View institutional ownership trends
.

How do I buy shares of Karuna Therapeutics?

Shares of KRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KRTX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners